A Medical Device Daily

Roche Diagnostics (Basel, Switzerland) said that it has decided to terminate its four-year collaboration with Epigenomics (Berlin/Seattle) to develop prostate, breast, and colorectal cancer screening diagnostic tests based on Epigenomics' DNA methylation technologies. Roche determined that the colorectal cancer screening data presented by Epigenomics to date did not meet Roche criteria for development as in vitro diagnostic tests.

In other agreements news:

Osiris Therapeutics (Baltimore) and AlloSource (Centennial, Colorado) reported that they have reached a multi-year agreement for the supply of orthopedic tissue. AlloSource will provide bone matrix to Osiris for use in the production of its Osteocel product line. Osteocel will be available from AlloSource to patients in all of AlloSource's donor areas across the country. AlloSource is one of the nation's largest non-profit providers of bone and soft tissue allografts, as well as allograft skin for burn applications, for use in surgical procedures.